The Centers for Disease Control and Prevention's vaccine advisory committee wrapped up the first day of its meeting since ...

A sign of the CDC is seen on a podium during the meeting of the members of the Advisory Committee on Immunization Practices, ...

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.